Table 1.

Donor and recipient characteristics KTX.

Variable	Total (n = 50)	ATG-perfused (n = 24)	Control-perfused (n = 26)	p-value#
Recipient age (yrs ± SD)*	54 ± 14	56 ± 13	53 ± 15	0.465
Recipient gender (females)***	14/50	7/24	7/26	1.000
Recipient BMI (kg/m2 ± SD)*	25 ± 5	25 ± 5	26 ± 5	0.571
Cold ischemic time (hours + IQR)**	13 (7)	11 (7)	14 (7)	0.222
Warm ischemic time (min + IQR)**	26 (10)	25 (10)	27 (8)	0.151
HLA Mismatch (number ± SD)*	3.4 ± 1	3.2 ± 2	3.6 ± 1	0.265
Panel reactive antibodies ≥20%***	0/50 (0%)	0/24 (0%)	0/26 (0%)	1.000
DISEASE***
Polycystic kidney disease	11/50 (22%)	6/24 (25%)	5/26 (19%)
Diabetes Typ II	5/50 (10%)	3/24 (13%)	2/26 (8%)
IgA nephropathy	4/50 (8%)	1/24 (4%)	3/26 (12%)
Glomerulonephritis	4/50 (8%)	2/24 (8%)	2/26 (8%)
Hypertensive nephropathy	4/50 (8%)	2/24 (8%)	2/26 (8%)
Intestinal or pyelonephritis	3/50 (6%)	2/24 (8%)	1/26 (4%)
Alport syndrome	2/50 (4%)	0/24 (0%)	2/26 (8%)
Renal vascular disease	1/50 (2%)	0/24 (0%)	1/26 (4%)
Diabetes Typ I	1/50 (2%)	1/24 (4%)	0/26 (0%)
Membranoproliferative glomerulonephritis	1/50 (2%)	0/24 (0%)	1/26 (4%)
Chronic pyelonephritis	1/50 (2%)	0/24 (0%)	1/26 (4%)
Amyloidosis	1/50 (2%)	1/24 (4%)	0/26 (0%)
Focal segmental glomerulosclerosis	1/50 (2%)	1/24 (4%)	0/26 (0%)
Analgesic nephropathy	1/50 (2%)	0/24 (0%)	1/26 (4%)
Uncertain etiology	10/50 (20%)	5/24 (21%)	5/26 (19%)
DGF (dialysis after Tx)	26/50	10/24	16/26	0.257
Recipient ICU stay (days + IQR)**	1 (1)	1 (1)	1 (2)	0.855
Hospital stay (days + IQR)**	13 (14)	16 (18)	12 (11)	0.164
Donor age (yrs ± SD)*	51 ± 17	51 ± 17	51 ± 18	0.933
Donor BMI (kg/m2 ± SD)*	26± 5	25 ± 4	26 ± 6	0.439
ECD Criteria***	21/50 (42%)	8/24 (33%)	13/26 (50%)	0.233

^*Mean + standard deviation;

^**median + interquartile range;

^***count (percentage);

^#differences between ATLG and control.